parallel review pilot FDA, CMS Make Parallel Review Program Permanent; Will Device and Diagnostic Companies Engage? Premium After a five-year pilot, only one company has successfully taken a test through parallel review, but there is growing industry interest. Foundation Medicine Pursuing Parallel Review by FDA, CMS for FoundationOne The company hopes to simultaneously achieve premarket FDA approval and a national coverage determination from CMS for its NGS cancer panel. With Top-line Deep-C Trial Data, Exact Sciences Gears Up for FDA and CMS Submissions for Cologuard Premium Originally published April 23. Exact Sciences Discusses Benefits of Taking Cologuard through FDA/CMS Parallel Review Pilot Premium Originally published April 2. FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says Premium Originally published Dec. 5. By Turna Ray Oct 12, 2011 FDA, CMS Parallel Review Pilot Opens Opportunities for Personalized Medicine Molecular Dx Premium Breaking News GenomeWeb Index Falls 6 Percent in November as Emergence of Omicron Spooks Markets Sequencing-Based MRD Detection in Bone Marrow May Predict ALL Relapse After CAR T-Cell Therapy Metabolomic Study Links 13 Metabolites to Coronary Heart Disease Risk Among African Americans Illumina Wins $8M Jury Verdict in BGI Patent Infringement Suit, Loses Patent Caris Life Sciences Facing FTC Lawsuit After Resisting Subpoena in Illumina, Grail Antitrust Case Biodesix, Spesana Partner to Improve Workflows for Lung Cancer Molecular Diagnostic Tests The Scan Panel Votes for COVID-19 Pill A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says. But Not Harm New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare. Effectiveness Drop Anticipated Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports. Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.